Chenard M P, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, Basset P, Bellocq J P, Duffy M J
Service d'Anatomie Pathologique Générale, Hôpitaux Universitaires deStrasbourg, Hopital de Hautepierre, France.
Int J Cancer. 1996 Dec 20;69(6):448-51. doi: 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.0.CO;2-4.
Stromelysin 3 (ST3) is a matrix metalloprotease (MMP) expressed in fibroblast-like cells of most human invasive carcinomas. In this investigation, ST3 was measured by semiquantitative immunohistochemistry in 111 primary breast cancers. ST3 levels showed no correlation with tumor size, axillary-node status or tumor grade (Scarff-Bloom-Richardson system; SBR) but were significantly associated with higher nuclear grade (modified SBR). In addition, ST3 levels were significantly higher in ductal than in lobular cancers. Patients with high scores of ST3 staining had a shorter disease-free interval and shorter overall survival than patients with low scores. ST3 is thus one of the first MMPs to correlate with patient outcome in breast cancer. These findings are consistent with earlier clinical and experimental observations suggesting that ST3 contributes to breast-cancer progression.
基质溶解素3（ST3）是一种在大多数人类浸润性癌的成纤维细胞样细胞中表达的基质金属蛋白酶（MMP）。在本研究中，通过半定量免疫组织化学法检测了111例原发性乳腺癌中的ST3。ST3水平与肿瘤大小、腋窝淋巴结状态或肿瘤分级（斯卡夫-布卢姆-理查森系统；SBR）无关，但与较高的核分级（改良SBR）显著相关。此外，导管癌中的ST3水平显著高于小叶癌。ST3染色高分患者的无病间期和总生存期均短于低分患者。因此，ST3是首批与乳腺癌患者预后相关的MMP之一。这些发现与早期临床和实验观察结果一致，表明ST3促进乳腺癌进展。
